A First-in-Human Study of HLA-Partially to Fully Matched Allogeneic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic Malignancies
Phase 1/2
12
about 2.4 years
18–75
9 sites in CA, FL, GA +5
What this study is about
This trial is testing the safety and feasibility of a bone marrow transplant from a deceased donor in people with leukemia, myelodysplastic syndrome, and certain lymphomas. Participants will receive either myeloablative or reduced intensity conditioning before the transplant. They will be followed for 56 days to monitor safety and remain under follow-up for one year.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Ossium HPC Marrow, Bone Marrow Transplant
- 2.Post-transplant treatment
- 3.Pre-transplant conditioning - Myeloablative (MAC)
- +1 more
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Primary: CTCAE Grade 3/4 Adverse Events (AEs), CTCAE Grade 3/4 Adverse Events (AEs) attributed to infusion of Ossium HPC, Marrow, Death, Serious Adverse Events
Oncology